110 related articles for article (PubMed ID: 20338618)
1. Exploring the peritoneal surface malignancy phenotype--a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models.
Flatmark K; Davidson B; Kristian A; Stavnes HT; Førsund M; Reed W
Hum Pathol; 2010 Aug; 41(8):1109-19. PubMed ID: 20338618
[TBL] [Abstract][Full Text] [Related]
2. MUC2 is a molecular marker for pseudomyxoma peritonei.
O'Connell JT; Hacker CM; Barsky SH
Mod Pathol; 2002 Sep; 15(9):958-72. PubMed ID: 12218214
[TBL] [Abstract][Full Text] [Related]
3. Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
McKenney JK; Soslow RA; Longacre TA
Am J Surg Pathol; 2008 May; 32(5):645-55. PubMed ID: 18344868
[TBL] [Abstract][Full Text] [Related]
4. Pseudomyxoma peritonei--two novel orthotopic mouse models portray the PMCA-I histopathologic subtype.
Flatmark K; Reed W; Halvorsen T; Sørensen O; Wiig JN; Larsen SG; Fodstad Ø; Giercksky KE
BMC Cancer; 2007 Jun; 7():116. PubMed ID: 17603904
[TBL] [Abstract][Full Text] [Related]
5. MUC2, MUC5AC and MUC5B in the mucus of a patient with pseudomyxoma peritonei: biochemical and immunohistochemical study.
Mall AS; Chirwa N; Govender D; Lotz Z; Tyler M; Rodrigues J; Kahn D; Goldberg P
Pathol Int; 2007 Aug; 57(8):537-47. PubMed ID: 17610480
[TBL] [Abstract][Full Text] [Related]
6. A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei.
Bibi R; Pranesh N; Saunders MP; Wilson MS; O'dwyer ST; Stern PL; Renehan AG
Br J Cancer; 2006 Nov; 95(9):1258-64. PubMed ID: 17031402
[TBL] [Abstract][Full Text] [Related]
7. [Expression and clinical significance of Mucin and E-cadherin in colorectal tumors].
Yu XW; Rong W; Xu FL; Xu GY; Sun YR; Feng MY
Ai Zheng; 2007 Nov; 26(11):1204-10. PubMed ID: 17991319
[TBL] [Abstract][Full Text] [Related]
8. Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells.
O'Connell JT; Tomlinson JS; Roberts AA; McGonigle KF; Barsky SH
Am J Pathol; 2002 Aug; 161(2):551-64. PubMed ID: 12163380
[TBL] [Abstract][Full Text] [Related]
9. Clinically aggressive pseudomyxoma peritonei: a variant of a histologically indolent process.
Mohamed F; Gething S; Haiba M; Brun EA; Sugarbaker PH
J Surg Oncol; 2004 Apr; 86(1):10-5. PubMed ID: 15048674
[TBL] [Abstract][Full Text] [Related]
10. [Ovarian mucinous adenocarcinoma, mucocele of the appendix and pseudomyxoma peritonei: case report with immunohistochemical analysis].
Singh A; Winkler M; Handt S; Rath W
Zentralbl Gynakol; 2000; 122(3):175-8. PubMed ID: 10756603
[TBL] [Abstract][Full Text] [Related]
11. Pseudomyxoma peritonei. A clinicopathologic study of 19 cases with emphasis on site of origin and nature of associated ovarian tumors.
Prayson RA; Hart WR; Petras RE
Am J Surg Pathol; 1994 Jun; 18(6):591-603. PubMed ID: 8179074
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical expressions of cytokeratins, mucin core proteins, p53, and neuroendocrine cell markers in epithelial neoplasm of appendix.
Yajima N; Wada R; Yamagishi S; Mizukami H; Itabashi C; Yagihashi S
Hum Pathol; 2005 Nov; 36(11):1217-25. PubMed ID: 16260276
[TBL] [Abstract][Full Text] [Related]
13. Histopathologic analysis in 46 patients with pseudomyxoma peritonei syndrome: failure versus success with a second-look operation.
Yan H; Pestieau SR; Shmookler BM; Sugarbaker PH
Mod Pathol; 2001 Mar; 14(3):164-71. PubMed ID: 11266521
[TBL] [Abstract][Full Text] [Related]
14. Mucinous Balls Tangled With Mesothelial Cells and MUC2-Positive Cancer Cells in the Ascites of Pseudomyxoma Peritonei.
Akashi S; Kuwabara H; Yasuda E; Akutagawa H; Takeshita A; Kurisu Y; Egashira Y; Hirose Y; Yuki M; Tsuda Y; Hayashi M
Diagn Cytopathol; 2016 Jul; 44(7):628-31. PubMed ID: 27079739
[TBL] [Abstract][Full Text] [Related]
15. Mucin gene expression in intraductal papillary-mucinous pancreatic tumours and related lesions.
Terris B; Dubois S; Buisine MP; Sauvanet A; Ruszniewski P; Aubert JP; Porchet N; Couvelard A; Degott C; Fléjou JF
J Pathol; 2002 Aug; 197(5):632-7. PubMed ID: 12210083
[TBL] [Abstract][Full Text] [Related]
16. Pseudomyxoma peritonei: new concepts in diagnosis, origin, nomenclature, and relationship to mucinous borderline (low malignant potential) tumors of the ovary.
Ronnett BM; Shmookler BM; Sugarbaker PH; Kurman RJ
Anat Pathol; 1997; 2():197-226. PubMed ID: 9575376
[TBL] [Abstract][Full Text] [Related]
17. Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases.
Vang R; Gown AM; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Ronnett BM
Am J Surg Pathol; 2006 Sep; 30(9):1130-9. PubMed ID: 16931958
[TBL] [Abstract][Full Text] [Related]
18. Mucinous ovarian tumors associated with pseudomyxoma peritonei of adenomucinosis type: immunohistochemical evidence that they are secondary tumors.
Ferreira CR; Carvalho JP; Soares FA; Siqueira SA; Carvalho FM
Int J Gynecol Cancer; 2008; 18(1):59-65. PubMed ID: 17511804
[TBL] [Abstract][Full Text] [Related]
19. [Expression of mucin MUC1 and MUC2 in colorectal carcinoma and their clinical significance].
Huang WB; Shi LH; Zhu XQ; Xu GX; Qi Q
Ai Zheng; 2002 Nov; 21(11):1231-4. PubMed ID: 12526222
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study.
Lau SK; Weiss LM; Chu PG
Am J Clin Pathol; 2004 Jul; 122(1):61-9. PubMed ID: 15272531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
